The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Open accessPublished version of a preprint
Abstract
Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. Experimental Design: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan–Meier analysis and Cox regression were applied for survival analysis. Results: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated with favorable OS in the discovery (n = 177) and the confirmation (n = 182) cohort and had independent positive impact (all P < 0.001). Their independent role was subsequently confirmed in the validation cohort (n = 257; all P < 0.01). The number of favorable factors was strongly associated with prognosis. One-year OS probabilities of 83.9% versus 14.7% and response rates of 58.3% versus 3.3% were observed in patients with four of four compared to those with none of four favorable baseline factors present, respectively. Conclusions: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 22(22); 5487–96. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
In the citing paper
“Importantly, it has been shown that investigating several biomarkers in combination can improve treatment predictions (109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Blocking antibodies targeting PD-1 or its counterpart PD-L1 can prevent this form of T cell inactivation (1, 10, 18, 34) ensuring sustained antitumor activity.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cited by
Sorted by citations
Items 401–500 of 585
Cancer immunotherapy: A need for peripheral immunodynamic monitoring
Wang, W., Xia, X., Wu, S.-P., Guo, M., Lie, P., & He, J. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12793 · Cited by 8
Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients
Lau, K.-S., Liu, R., Wong, C. C., Siu, W., & Yuen, K.-K. (2019) · Annals of Palliative Medicine · doi:10.21037/apm.2019.10.03 · Cited by 8
Singh, N., Lubana, S. S., Constantinou, G., & Leaf, A. N. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/7492634 · Cited by 8
Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy
Hofbauer, J., Hauck, A., Matos, C., Babl, N., Decking, S.-M., Rechenmacher, M., Schulz, C. K. J., Regotta, S., Mickler, M., Haferkamp, S., et al. (2022) · Biomolecules · doi:10.3390/biom12050716 · Cited by 8
Gide, T. N., Mao, Y., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1109 · Cited by 7
Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors
Chen, S., Hu, Y., Cheng, H., Guo, S., Han, Y., & Li, K. (2026) · Biomarker Research · doi:10.1186/s40364-026-00892-5 · Cited by 7
Tabari, A., Cox, M., D’Amore, B., Mansur, A., Dabbara, H., Boland, G. M., Gee, M. S., & Daye, D. (2023) · Cancers · doi:10.3390/cancers15102700 · Cited by 7
A prediction model for response to immune checkpoint inhibition in advanced melanoma
van Duin, I. A. J., Verheijden, R. J., van Diest, P. J., Blokx, W. A. M., Sharouni, M. E., Verhoeff, J. J. C., Leiner, T., van den Eertwegh, A. J. M., de Groot, J. W. B., van Not, O. J., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34853 · Cited by 7
Self-citationSugase, T., Kanemura, T., Takeoka, T., Matsuura, N., Masuike, Y., Shinno, N., Hara, H., Kitakaze, M., Kubo, M., Mukai, Y., et al. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000529 · Cited by 7
Indini, A., Guardo, L. D., Cimminiello, C., Prisciandaro, M., Randon, G., de Braud, F., & Vecchio, M. D. (2019) · Tumori Journal · doi:10.1177/0300891619868009 · Cited by 7
Lin, G., Huang, X., Lü, J., Wu, D., Zheng, H., Xu, B., Zheng, C., Li, P., Xie, J., Wang, J.-B., et al. (2021) · Surgical Endoscopy · doi:10.1007/s00464-021-08461-7 · Cited by 7
Getting personal about skin: Realizing precision medicine in dermatology
Brownstone, N. D., Wu, J. J., Strober, B. E., & Dickerson, T. J. (2021) · Dermatological Reviews · doi:10.1002/der2.99 · Cited by 7
Teshima, T., Kobayashi, Y., Kawai, T., Kushihara, Y., Nagaoka, K., Miyakawa, J., Akiyama, Y., Yamada, Y., Sato, Y., Yamada, D., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13384 · Cited by 7
Guo, D., Zhang, S., Dong, S.-Y., Yan, J., Wang, Y., Cao, Y., Rao, S., Fan, J., Yang, X., Huang, A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1109742 · Cited by 7
Berking, C., Livingstone, E., Debus, D., Loquai, C., Weichenthal, M., Leiter, U., Kiecker, F., Mohr, P., Eigentler, T., Remy, J., et al. (2023) · Cancers · doi:10.3390/cancers15184436 · Cited by 7
Self-citationRiudavets, M., Auclin, É., Mosteiro, M., Dempsey, N. G., Majem, M., Prelaj, A., Castro, R. L., Bosch‐Barrera, J., Pilotto, S., Escalera, E., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.11.007 · Cited by 7
Shimoyama, R., Imamura, Y., Uryu, K., Mase, T., Shiragami, M., Fujimura, Y., Hayashi, M., Ohtaki, M., Ohtani, K., Shinozaki, N., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14269 · Cited by 7
Proteomics: An Indispensable Tool for Novel Biomarker Identification in Melanoma
Mittal, P., & Jain, M. (2016) · Journal of Data Mining in Genomics & Proteomics · doi:10.4172/2153-0602.1000204 · Cited by 7
Serum 5‐S‐cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients
Omodaka, T., Minagawa, A., Uhara, H., Wakamatsu, K., Koizumi, T., Yokokawa, Y., Koga, H., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14605 · Cited by 7
Bonomi, M. R., Bhateja, P., Issa, M., Klamer, B. G., Pan, X. J., Blakaj, A., Karivedu, V., Mousa, L., Mitchell, D., Gamez, M. E., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104900 · Cited by 7
Oyanagi, J., Koh, Y., Sato, K., Teraoka, S., Tokudome, N., Hayata, A., Akamatsu, H., Ozawa, Y., Nakanishi, M., Ueda, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.007 · Cited by 7
Kissoonsingh, P., Sutton, B., Iqbal, S. U., Pallan, L., Steven, N. M., & Khoja, L. (2022) · Case Reports in Oncological Medicine · doi:10.1155/2022/2658136 · Cited by 7
Shen, Y., Wang, J., Hua, Q., & Dong, M. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s557312 · Cited by 6
Beulque, Y., Kinget, L., Roussel, E., Mobaraki, S., Laenen, A., Debruyne, P. R., Herck, Y. V., Baldewijns, M. M. L. L., Woźniak, A., Garg, A. D., et al. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.40390 · Cited by 6
Brohet, R. M., de Boer, E. C. S., Mossink, J. M., van der Eerden, J. J. N., Oostmeyer, A., Idzerda, L. H. W., Maring, J. G., Paardekooper, G., Beld, M., Lijffijt, F., et al. (2025) · JCO Clinical Cancer Informatics · doi:10.1200/cci-24-00181 · Cited by 6
Lyu, X., Han, J., Chen, L., Zhou, Y., & Wang, W. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5762 · Cited by 6
Immune signatures predicting responses to immunomodulatory antibody therapy
Pawelec, G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.003 · Cited by 6
A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma
Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 6
Brand, C. L., Hunger, R. E., & Jafari, S. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366081 · Cited by 6
Cimminiello, C., Indini, A., Guardo, L. D., Prisciandaro, M., Randon, G., Tolomio, E., de Braud, F., & Vecchio, M. D. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000539 · Cited by 6
Burgermeister, S., Gabryś, H. S., Basler, L., Hogan, S. A., Pavic, M., Bogowicz, M., Gómez, J. M. M., Vuong, D., Tanadini‐Lang, S., Foerster, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830627 · Cited by 6
Self-citationKoczka, K., Rigo, R., Batuyong, E., Cook, S. B., Asad, M., Vallerand, I. A., Suo, A. E., Wang, E., & Cheng, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5070 · Cited by 6
Prelaj, A., Russo, G. L., Proto, C., Signorelli, D., Ferrara, R., Galli, G., Toma, A. D., Randon, G., Pagani, F., Trevisan, B., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.005 · Cited by 6
Salzmann, M., Wald, A., Stege, H. M., Loquai, C., Zimmer, L., Hayani, K. M., Heinzerling, L., Gutzmer, R., Enk, A., & Hassel, J. C. (2023) · Cancers · doi:10.3390/cancers15051426 · Cited by 5
Self-citationReview of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment
Mima, Y., Ohtsuka, T., Ebato, I., Nakata, Y., Tsujita, A., Nakazato, Y., & Norimatsu, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12081886 · Cited by 5
Ugurel, S., Kiecker, F., Fröhling, S., Wetter, A., Bánkfalvi, Á., Sucker, A., Zimmer, L., Livingstone, E., Roesch, A., Becker, J. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.020 · Cited by 5
Self-citationPan, Y., Si, H., Jia, R., Deng, G., Yan, H., Fan, M., Gou, M., Chen, S., Zhang, N., Shi, Y., et al. (2022) · Journal of Oncology · doi:10.1155/2022/1427779 · Cited by 5
Foerster, Y., Mayer, K. E., Wasserer, S., Dechant, M., Verkhoturova, V., Heyer, S., Biedermann, T., & Persa, O. (2025) · Cancer Medicine · doi:10.1002/cam4.70631 · Cited by 5
Li, W.-J., Lin, Z., & Wang, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1742 · Cited by 5
Charles, J., Chaperot, L., Revol, B., Baudin, M., Mouret, S., Hamon, A., Leccia, M. ‐., Plumas, J., & Aspord, C. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12618 · Cited by 5
Ikoma, T., Matsumoto, T., Kurioka, Y., Takatani, M., Nagai, H., Matsumoto, Y., Satake, H., & Yasui, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206100 · Cited by 5
Paver, E. C., Gide, T. N., Yaseen, Z., Cornejo‐Páramo, P., Ferguson, P. M., Maher, N. G., Menzies, A. M., Carlino, M. S., da Silva, I. P., Holst, J., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03637-8 · Cited by 4
Matsumiya, M., Sonoda, H., Yamashita, H., Kurashina, K., Takahashi, K., Ohzawa, H., Miyato, H., Matsumoto, S., Saito, S., Hosoya, Y., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-025-19075-x · Cited by 4
Biomarkers for immune checkpoint inhibitors in solid tumors
Kapoor, V., & Kelly, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02942-4 · Cited by 4
Mattila, K., Mäkelä, S., Kytölä, S. I., Andersson, E. I., Vihinen, P., Ramadan, S., Skyttä, T., Tiainen, L., Vuoristo, M., Tyynelä-Korhonen, K., et al. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2137693 · Cited by 4
Peisen, F., Gerken, A., Hering, A., Dahm, I. C., Nikolaou, K., Gatidis, S., Eigentler, T., Amaral, T. M. S., Moltz, J. H., & Othman, A. E. (2023) · Diagnostics · doi:10.3390/diagnostics13203210 · Cited by 4
Prognostic Value of the Lung Immune Prognostic Index for HER-2-Negative Metastatic Gastric Cancer
Gou, M., Yong, Z., Qu, T., Jia, R., Wang, Z., & Dai, G. (2023) · Biomarkers in Medicine · doi:10.2217/bmm-2023-0052 · Cited by 4
Mokbel, S., Baciarello, G., Lavaud, P., Omlin, A. G., Calabrò, F., Cathomas, R. L., Aeppli, S., Parent, P., Giannatempo, P., Koster, K., et al. (2024) · Cancers · doi:10.3390/cancers16081465 · Cited by 4
Diamantopoulos, P. T., Gkoufa, A., Anastasopoulou, A. N., Kouzis, P., Lyrarakis, G., Kyriakakis, G., & Gogas, H. J. (2025) · Cancer Medicine · doi:10.1002/cam4.70679 · Cited by 4
Liu, Y. T., Goel, S., Kai, M., Moran-Guerrero, J. A., Nguyen, T. U., Mai, J., Shen, H., Žiemys, A., & Yokoi, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040530 · Cited by 4
Grabbe, P., Gschwendtner, K. M., Maatouk, I., Strobel, S. B., Salzmann, M., Bossert, J., Eich, W., Wild, B., Meier, F. E., Hassel, J. C., et al. (2021) · Trials · doi:10.1186/s13063-021-05234-4 · Cited by 4
Self-citationZaretsky, A. R., Демидов, Л. В., & Самойленко, И. В. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-9-48-63 · Cited by 4
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Harada, M., Tamura, S., Kobayashi, H., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s389138 · Cited by 4
Peisen, F., Gerken, A., Dahm, I. C., Nikolaou, K., Eigentler, T., Amaral, T. M. S., Moltz, J. H., Othman, M. I. A., & Gatidis, S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296253 · Cited by 4
Vacher, L., Bernadach, M., Molnar, I., Passildas, J., & Dubray‐Longeras, P. (2024) · Health Science Reports · doi:10.1002/hsr2.1825 · Cited by 4
Hou, Q., & Xu, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_7 · Cited by 4
Diagnosis of Stage IV Melanoma
Tarhini, A. A., Agarwala, S. S., Khunger, A., Wahl, R. L., & Balch, C. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_29 · Cited by 4
Degenhardt, S., Bender, M., Chen, I.-P., Henning, S. W., Mhamdi-Ghodbani, M., Starzonek, C., Mohr, P., Gebhardt, C., Pantel, K., Volkmer, B., et al. (2024) · Journal of Cancer Genetics and Biomarkers · doi:10.14302/issn.2572-3030.jcgb-24-4970 · Cited by 3
Self-citationEosinophils in solid cancers: sentinels, predictors, and therapeutic allies
Gilon, M., Boulet, D., Bours, V., Jérusalem, G., Josse, C., & Gennigens, C. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03688-5 · Cited by 3
Uchida, T., Nakagome, K., Hashimoto, K., Iemura, H., Shiko, Y., Mouri, A., Yamaguchi, O., Uchida, Y., Nagai, Y., Soma, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574314 · Cited by 3
Predictive biomarkers in clinical practice: State of the art and perspectives in solid tumors
Ulivi, P. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820904964 · Cited by 3
Yang, Y., Liu, X., Song, W., Jin Wei, L. U., Yin, N., Ye, X., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907705 · Cited by 3
Liu, X., Liu, S., Jiang, Z., Yang, C., Yang, X., Li, J., & Liu, H. (2023) · Immunotherapy · doi:10.2217/imt-2023-0105 · Cited by 3
Ali, W. A. S., Huang, X., Wu, Y., Ma, Y., Pan, H., Liao, J., Zhang, Y., Hong, S., Yang, Y., Huang, Y., et al. (2023) · Cancer Control · doi:10.1177/10732748221148912 · Cited by 3
Li, S., Wang, Y., Cai, H., Pan, Z., & Guan, G. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04474-x · Cited by 3
Biomarqueurs tissulaires des immunothérapies anti-PD-1 dans le mélanome
Adam, J., Tomasic, G., & Robert, C. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.011 · Cited by 3
Hooiveld-Noeken, J. S., Fehrmann, R. S. N., de Vries, E. G. E., & Jalving, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.11.002 · Cited by 3
Carnio, S., Mariniello, A., Pizzutilo, P., Numico, G., Borra, G., Lunghi, A., Parra, H. J. S., Buosi, R., Vavalà, T., Stura, I., et al. (2020) · Journal of Molecular Pathology · doi:10.3390/jmp1010004 · Cited by 3
Inflammatory Infiltrates in Melanocytic Lesions
Relan, A., Desar, S., Dunnette, B., Shanley, R., & Giubellino, A. (2021) · International Journal of Morphology · doi:10.4067/s0717-95022021000200512 · Cited by 3
Resistance patterns to anti-PD-1 therapy in metastatic melanoma
Özgün, A., Sondak, V. K., & Markowitz, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.08.01 · Cited by 3
Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer
Pan, Y., Ma, Y., & Guang-hai, D. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03612-3 · Cited by 2
Elevated Lactic Acid Levels in the Aqueous Humor May Be an Indicator of Uveal Melanoma
Miller, S. C., Cano, M., Kawalerski, R. R., Shi, M. D., Sodhi, A., Merbs, S. L., Rajaii, F., Hu, D., Eberhart, C. G., & Handa, J. T. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.09.014 · Cited by 2
Gambichler, T., Overbeck, J., Rached, N. A., Susok, L., & Weyer-Fahlbusch, S. S. (2025) · Journal of Skin Cancer · doi:10.1155/jskc/2561307 · Cited by 2
Biomarkers as Drivers of Innovation in Modern Diagnostics and Therapeutics
Soni, S., Rathee, S., & Jain, S. (2026) · Current Drug Targets · doi:10.2174/0113894501419834251129045230 · Cited by 2
Beypınar, İ., Balçık, O. Y., Urvay, S., Ürün, M., Erçek, B. M., Demir, H., Yıldız, C., Araz, M., Oruç, A. F., İlhan, Y., et al. (2026) · Biomarkers · doi:10.1080/1354750x.2026.2621291 · Cited by 2
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., MASAOKA, H., Harada, M., Tamura, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16666 · Cited by 2
Pan, C., Ng, K., Voutsinas, J. M., Barber, B. R., Rizvi, Z. H., Marchiano, E. J., Ferrandino, R. M., Futran, N. D., Laramore, G. E., Liao, J. J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13051-6 · Cited by 2
Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy
Karaoğlan, B. B., Dursun, E., Mesci, İ., Araz, M., & Köksoy, E. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-16788-7 · Cited by 2
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
Hattori, T., Ueda, T., Sato, Y., Chikuie, N., Taruya, T., Hamamoto, T., Hattori, M., Ishino, T., & Takeno, S. (2024) · Acta Oto-Laryngologica · doi:10.1080/00016489.2024.2390084 · Cited by 2
Scherrer, E., Rau, R., Lorenzi, M. F., Shui, I. M., Townson, S. M., & Larkin, J. (2021) · Future Oncology · doi:10.2217/fon-2021-0154 · Cited by 2
Melanoma: An immunotherapy journey from bench to bedside
Navani, V., Graves, M. C., Mandaliya, H. A., Hong, M., van der Westhuizen, A., Martin, J. H., & Bowden, N. A. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_2 · Cited by 2
Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy
Sheppard, A. D., & Lysaght, J. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0802-9_17 · Cited by 2
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab
Puri, S., & Markowitz, J. (2017) · Annals of Research Hospitals · doi:10.21037/arh.2017.04.24 · Cited by 2
Paidi, S. K., Troncoso, J. R., Raj, P., Díaz, P. M., Lee, D. E., Rajaram, N., & Barman, I. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2011.05304 · Cited by 2
Mattila, K., Tiainen, L., Vikkula, J., Kreutzman, A. S., Engström-Risku, M., Kysenius, K., Hölsä, O., Hernesniemi, S., Hemmilä, P., Pystynen, A., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2403329 · Cited by 1
Palli, E., Lavigne, M. D., Verginis, P., Alissafi, T., Anastasopoulou, A. N., Lyrarakis, G., Kirkwood, J. M., Gogas, H. J., & Ziogas, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529707 · Cited by 1
Saadani, H., Aalbersberg, E. A., Kayembe, M. T., Haanen, J. B. A. G., Hoekstra, O. S., Boellaard, R., & Stokkel, M. P. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-95713-4 · Cited by 1
Jin, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1675411 · Cited by 1
Duan, Q., Zhang, X., & Li, M. (2025) · Cancer Management and Research · doi:10.2147/cmar.s564116 · Cited by 1
Sugase, T., Kanemura, T., Matsuura, N., Yamamoto, K., Ushimaru, Y., Masuike, Y., Yanagimoto, Y., Yamamoto, K., Sakano, Y., Mori, R., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19648-4 · Cited by 1
Zheng, L., Yang, J., Chen, X., Li, L., & Sun, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163807 · Cited by 1
Lobo-Martins, S., Martins-Branco, D. A., Semedo, P. M., Alvim, C. M., Monteiro, A. M., Vendrell, I., Gouveia, E. J., Passos, M. J., Costa, L., Mansinho, A., et al. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101043 · Cited by 1
Bentebibel, S.-E., McGrail, D. J., Kochat, V., Arslan, E., Abdel‐Wahab, R., Pazdrak, B., Murthy, R., Tahon, N. H., Cho, S. H., Duose, D. Y., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1551 · Cited by 1
Zhao, N., Wu, X., Zhao, W., Cheng, X., He, H., & Cao, D. (2026) · BMC Cancer · doi:10.1186/s12885-026-16302-w · Cited by 1
Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance
Kim, D. W., Uemura, M. I., & Diab, A. K. (2017) · Journal of Biomedical Sciencies · doi:10.4172/2254-609x.100058 · Cited by 1
Predictive biomarkers of response for PD-1/PD-L1 inhibitors: a cumbersome gold rush
Vingiani, A., Barberis, M. C. P., & Guerini‐Rocco, E. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0054 · Cited by 1
Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma
Semiz, H. S. (2020) · International Journal of Hematology and Oncology · doi:10.4999/uhod.204187 · Cited by 1
Biomarkers for Immune Checkpoint Inhibitors
Sharif, P. M., Keshavarz‐Fathi, M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_25 · Cited by 1
Schadendorf, D., Flaherty, K. T., Duncan, L. M., Kashani–Sabet, M., & Ugurel, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_45 · Cited by 1
Self-citation
Metadata
- Authors
- Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., Brenner, N., Kähler, K., Heinzerling, L., Gutzmer, R., Bender, A., Gebhardt, C., Romano, E., Meier, F., Martus, P., Maio, M., Blank, C., Schadendorf, D., Dummer, R., Ascierto, P. A., Hospers, G., Garbe, C., & Wolchok, J. D.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Heidelberg University (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Memorial Sloan Kettering Cancer Center (US)
- University Medical Center Groningen (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- 10Department of Dermatology, University of Zürich, Zürich, Switzerland.
- 12Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
- University Hospital Cologne (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsklinikum Erlangen (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- German Cancer Research Center (DE)
- Institut Curie (FR)
- University of Tübingen (DE)
- University of Siena (IT)
- The Netherlands Cancer Institute (NL)
- University of Zurich (CH)
- Corresponding author
- Weide, Benjamin
- ORCID
- Weide, Benjamin
- Hassel, Jessica C.
- Berking, Carola
- Postow, Michael A.
- Bisschop, Kees
- Simeone, Ester
- Schilling, Bastian
- Brenner, Nicole
- Kähler, Katharina
- Heinzerling, Lucie
- Gutzmer, Ralf
- Gebhardt, Christoffer
- Romano, Emanuela
- Meier, Friedegund
- Martus, Peter
- Maio, Michele
- Blank, Christian
- Schadendorf, Dirk
- Dummer, Reinhard
- Ascierto, Paolo A.
- Hospers, Geke
- Garbe, Claus
- Wolchok, Jedd D.
- Venue
- Clinical Cancer Research
- Published
- 2016-11-14
- Volume
- 22
- Issue
- 22
- Pages
- 5487-5496
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5572569
- OpenAlex
- W2397854274
- Semantic Scholar
- b5a9c4e2d6333e54d55ec140895bb53cebb851f9
- Cited by
- 589
- References
- 44
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 31 · 2023: 46 · 2022: 57 · 2021: 91 · 2020: 86 · 2019: 77 · 2018: 72 · 2017: 59 · 2016: 14
- FWCI
- 39.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, pembrolizumab, immune checkpoint blockade, prognostic factors, overall survival, lactate dehydrogenase, eosinophil count, lymphocyte count, metastasis, best overall response, predictive biomarkers
- MeSH terms
- Aged, Antibodies, Monoclonal, Female, Humans, L-Lactate Dehydrogenase, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Biomarkers, Tumor, Cohort Studies, Survival Analysis, Treatment Outcome, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
